Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rankning i aktier #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aktiekurs
$0.00244926
Marknadsvärde
$51.67K
Förändring (1 dag)
5.88%
Förändring (1 år)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Kategori

EPS för Nuformix plc (NFX)
EPS per September 2025 TTM: $0.00
Enligt Nuformix plcs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $0.00. Vid slutet av 2024 hade bolaget ett EPS på $-0.01, en minskning jämfört med EPS från 2023 som var $0.00.
EPS-historik för Nuformix plc från 2014 till 2026
EPS vid slutet av varje år
År EPS Ändra
2026 (TTM) 0.00 -100.00%
2025 0.00 -100.00%
2024 $-0.01 520.00%
2023 0.00 -60.00%
2022 0.00 -16.67%
2021 0.00 50.00%
2020 0.00 -57.45%
2019 0.00 -31.88%
2018 $-0.01 -23.33%
2017 $-0.01 8.43%
2016 $-0.01 0.00%
2014 0.00 0.00%
EPS för liknande företag eller konkurrenter
Företag EPS EPS-differens Land
$3.62 -402,577.78%
DK
$15.47 -1,718,988.89%
US
$43.12 -4,791,211.11%
US
$9.62 -1,069,077.78%
BE
$2.98 -331,211.11%
AU